These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23776587)

  • 21. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.
    Wu S; Gan Y; Wang X; Liu J; Li M; Tang Y
    J Cancer Res Clin Oncol; 2013 May; 139(5):891-900. PubMed ID: 23435830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
    Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
    J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
    Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
    Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
    Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
    Wang JX; Wu HL; Zhu M; Zhou R
    Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
    Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
    Eur J Cancer; 2016 Mar; 55():122-30. PubMed ID: 26812186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
    Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.
    Yang ZY; Shen WX; Hu XF; Zheng DY; Wu XY; Huang YF; Chen JZ; Mao C; Tang JL
    J Hematol Oncol; 2012 Aug; 5():52. PubMed ID: 22897982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of
    Santos C; Azuara D; Garcia-Carbonero R; Alfonso PG; Carrato A; Elez ME; Gomez A; Losa F; Montagut C; Massuti B; Navarro V; Varela M; Lopez-Doriga A; Moreno V; Valladares M; Manzano JL; Vieitez JM; Aranda E; Sanjuan X; Tabernero J; Capella G; Salazar R
    Mol Cancer Ther; 2017 Sep; 16(9):1999-2007. PubMed ID: 28626084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies.
    Wang ZH; Gao QY; Fang JY
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1647-55. PubMed ID: 22610356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.
    Zlobec I; Molinari F; Kovac M; Bihl MP; Altermatt HJ; Diebold J; Frick H; Germer M; Horcic M; Montani M; Singer G; Yurtsever H; Zettl A; Terracciano L; Mazzucchelli L; Saletti P; Frattini M; Heinimann K; Lugli A
    Br J Cancer; 2010 Jan; 102(1):151-61. PubMed ID: 19935791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis.
    Zhou M; Yu P; Hou K; Fu L; Chen Y; Qu J; Qu X; Liu Y; Zhang J
    Meta Gene; 2016 Sep; 9():110-9. PubMed ID: 27331015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.
    Modest DP; Jung A; Moosmann N; Laubender RP; Giessen C; Schulz C; Haas M; Neumann J; Boeck S; Kirchner T; Heinemann V; Stintzing S
    Int J Cancer; 2012 Aug; 131(4):980-6. PubMed ID: 21960311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.